Agenzia Italiana del Farmaco
Definitive cessation of marketing of Emend (aprepitant) - Definitive cessation of marketing of Emend (aprepitant)
Definitive cessation of marketing of Emend (aprepitant)
MSD Italia S.r.l., local representative of Merck Sharp & Dohme B.V., has notified AIFA and the European Regulatory Authorities of the permanent marketing cessation of EMEND (aprepitant) in the European Union/European Economic Area.
This decision is based on commercial reasons and is not related to any concerns regarding the safety, efficacy or quality of the medicinal product. In Italy, the permanent marketing cessation of EMEND 125 mg + 80 mg hard capsules is currently expected from 30 November 2026.
Healthcare professionals are advised to review ongoing treatment plans and consider appropriate therapeutic alternatives for affected patients in order to ensure continuity of care.
Published on: 16 November 2026
